For Illumina, its former employees are both a boon and a problem. In the 27 years since its founding, the DNA sequencing ...

The CDC will no longer recommend routine Covid-19 vaccines for healthy kids and pregnant women after HHS Secretary Robert F.

Prothena abandons birtamimab after Phase 3 amyloidosis trial failure, plans layoffs. Drug previously failed mid-stage trial.

Bio­gen is div­ing in­to the RNAi field with City Ther­a­peu­tics, a biotech led by sev­er­al for­mer Al­ny­lam lead­ers.

Protein degrader shop GlycoEra, spun out of vaccines company LimmaTech in 2021, has corralled $130 million in Series B ...

The Column Group's drug R&D team, known as TCG Labs Soleil, has been busy churning out new portfolio companies since it ...

Arvinas' vepdegestrant shows 43% reduced risk of progression or death in ESR1-mutated breast cancer patients vs hormone ...

Hetero Labs could launch its generic sleep disorder drug as early as 2040 under a settlement deal with Axsome Therapeutics.

As of Thursday morning, just over 300 entries out of at least 950 public comments have been released by the Department of ...

Strand Therapeutics reports early positive data for STX-001, a self-replicating mRNA cancer therapy, showing safety and ...

InflaRx halts Phase 3 trial of Gohibic for pyoderma gangrenosum after interim analysis shows likely failure; will focus on ...

Indy biotech Syndeio launches with $90M, led by CEO Derek Small, to develop NMDA receptor drugs for depression & Alzheimer's, ...